REGULATORY
ESMO Updates Guidelines for Metastatic Colorectal CancerNew ESMO Clinical Practice Guidelines establish structured treatment algorithms driven by MMR/MSI status, ECOG performance, tumor location, and extended molecular profiling including RAS, BRAF, HER2, and KRAS G12C. Key updates include first-line FOLFOX-encorafenib-cetuximab for BRAF V600E-mutated tumors and ctDNA-guided anti-EGFR rechallenge in refractory settings. (Annals of Oncology / OncoDaily)